Eli Lilly's top drug last year is softening. But it may not matter for the stock
Analysts see weak trends for Trulicity, which led all Eli Lilly drugs in sales last year. But that won't keep the stock from going higher.
Source: cnbc.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Both Lilly. Real-time updates on events, politics, business and more.